Last edition
News about
This allogeneic NK cell therapy, derived from healthy donors, exhibits potent anti-cancer effects characterized by high purity and activity.
Bayer and Evotec to Upgrade Precision Cardiology
Bayer and Evotec have updated the focus of their strategic collaboration to developing innovative precision treatments for cardiovascular diseases (CVDs).
Scenic Biotech Enters into Research Partnership with Bristol Myers Squibb
Scenic Biotech has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.
Neogen Launches New Molecular Method for Detection of Two Salmonella Serotypes
Neogen® Corporation announced the launch of the new Neogen Molecular Detection Assay 2 – Salmonella Enteritidis/Salmonella Typhimurium (MDA2SEST).
Genstar Names Keith Martino to Strategic Advisory Board
Genstar Capital announced the appointment of experienced pharma executive Keith Martino to its team of operational experts serving on its Strategic Advisory Board.
Evox Therapeutics Appoints Dr. Per Lundin as Chief Executive Officer
Evox Therapeutics Ltd. has announced the appointment of Dr. Per Lundin, Co-Founder and Chief Business Officer as Chief Executive Officer (CEO) and will be appointed to its Board of Directors.
Single Pass Receives FDA Clearance for Kronos Biopsy Closure Device
Under the leadership of Bill Colone and the Board of Directors, the Single Pass team collaborated with their contract manufacturing partner, M4D, located in Lake Forest, CA, to bring the Kronos device to market.
Miltenyi Biotec and MiLaboratories to Reform Next-Generation Therapies
Miltenyi Biotec has teamed up with MiLaboratories that promises to revolutionize the field of next-generation therapies.
Medit Unveils Intraoral Scanner: The Medit i900 Redefines Dental Technology Standards
Weighing a mere 165 grams, the i900 boasts a featherlight design, along with three tip sizes and improved ergonomics, allowing for precise scanning from any position.
ONO to Acquire Deciphera Pharma for USD 2.4 Billion
Deciphera Pharmaceuticals, Inc. has signed a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO).
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy